|MDACC Study No:||2013-0656 (clinicaltrials.gov NCT No: NCT01994837)|
|Title:||A Phase 2 Study of ABT-199 in Subjects with Acute Myelogenous Leukemia (AML)|
|Principal Investigator:||Marina Konopleva|
|Treatment Agent:||ABT-199 |
|Study Description:||The goal of this clinical research study is to learn if ABT-199 can help to |
control AML. The safety of this drug will also be studied.